Outcome of special types of luminal breast cancer

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1428-1436

  Colleoni, M ^a   Rotmensz, N ^a   Maisonneuve, P ^a   Mastropasqua, M G ^a,b   Luini, A ^a   Veronesi, P ^a   Intra, M ^a   Montagna, E ^a   Cancello, G ^a   Cardillo, A ^a   Mazza, M ^a   Perri, G ^a   Iorfida, M ^a   Pruneri, G ^a   Goldhirsch, A ^a   Viale, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; Special types

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RELAPSE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 84861719013     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr461     Document Type: Article

References (53)

1. Goldhirsch A, Ingle JN, Gelber RD et al. Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol 2009; 20: 1319-1329.
2. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
3. Page DL. Special types of invasive breast cancer, with clinical implications. Am J Surg Pathol 2003; 27: 832-835.
4. Ellis P, Schnitt SJ, Sastre-Garau X. Invasive breast carcinoma. In Tavassoli FA, Devilee P (eds); Pathology and Genetics of Tumours of the Breast and Female Genital Organs: WHO Classification of Tumours Series. Lyon, France: IARC Press 2003; 13-48.
5. Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol. 1993; 11: 2090-2100.
6. Rakha EA, Lee AHS, Evans AJ et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 2010; 28: 99-104.
7. Page DL, Dixon JM, Anderson TJ et al. Invasive cribriform carcinoma of the breast. Histopathology 1983; 7: 525-536.
8. Clayton F. Pure mucinous carcinomas of breast: morphologic features and prognostic correlates. Hum Pathol 1986; 17: 34-38.
9. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009; 6: 718-730.
10. Cheang MCU, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
11. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553.
12. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs: WHO Classification of Tumours Series. Lyon, France: IARC Press 2003; 13-48.
13. Rosen PP, Oberman HA. Atlas of Tumor Pathology: Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology 1992.
14. Colleoni M, Orvieto E, Nolé F et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999; 35: 574-579.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer-Experience from a large study with longterm follow-up. Histopathology 2002; 41: 151.
16. Rosen PP. Mucinous carcinoma. In Rosen PP (ed), Rosen's breast pathology, 3rd edition. Philadelphia, PA: Lippincott Williams and Wilkins 2009; 515-535.
17. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol 2009; 27: 1168-1176.
18. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights-International Consensus Panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90: 1601-1608.
19. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
20. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicincyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483-1496.
21. Colleoni M, Litman HJ, Castiglione-Gertsch M et al. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 2002; 86: 1705-1714.
22. Ellis IO, Galea M, Broughton N et al. Pathological prognostic factors in breast cancer: II. Histological type-relationship with survival in a large study with long-term follow-up. Histopathology 1992; 20: 479-489.
23. Fitzgibbons PL, Page DL, Weaver D et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-978.
24. Pereira H, Pinder SE, Sibbering DM et al. Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995; 27: 219-226.
25. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
26. Rosen PP. Cribriform carcinoma. In Rosen PP (ed), Rosen's Breast Pathology. 2nd Edition. Philadelphia, PA: Lippincott Williams & Wilkins 2001; 551-553.
27. Venable JG, Schwartz AM, Silverberg SG. Infiltrating cribriform carcinoma of the breast: a distinctive clinicopathologic entity. Hum Pathol 1990; 21: 333-338.
28. Louwman MWJ, Vriezen M, van Beek MPWM et al. Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 2007; 121: 127-135.
29. Abdel-Fatah TM, Powe DG, Hodi Z et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008; 32: 513-523.
30. Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216: 141-150.
31. Diab SG, Clark GM, Osborne CK et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999; 17: 1442-1448.
32. Deos PH, Norris HJ. Well-differentiated (tubular) carcinoma of the breast: a clinicopathologic study of 145 pure and mixed cases. Am J Clin Pathol 1982; 8: 1-7.
33. Green I, McCormick B, Cranor M et al. A comparative study of pure tubular and tubulolobular carcinoma of the breast. Am J Surg Pathol 1997; 21: 653-657.
34. Javid SH, Smith BL, Mayer E et al. Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg 2009; 197: 674-677.
35. Kitchen PR, Smith TH, Henderson MA et al. Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy. ANZ J Surg 2001; 71: 27-31.
36. Winchester DJ, Sahin AA, Tucker SL et al. Tubular carcinoma of the breast: predicting axillary nodal metastases and recurrence. Ann Surg 1996; 223: 342-347.
37. Lopez-Garcia MA, 1 Geyer FC, Natrajan R et al. Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. J Pathol 2010; 222: 64-75.
38. Komaki K, Sakamoto G, Sugano H et al. Mucinous carcinoma of the breast in Japan: a prognostic analysis based on morphologic features. Cancer 1988; 61: 989-996.
39. Weigelt B, Geyer FC, Horlings HM et al. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol 2009; 22: 1401-1404.
40. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008; 111: 541-547.
41. Toikkanen S, Kujari H. Pure and mixed mucinous carcinoma of the breast: a clinicopathologic analysis of 61 cases with long-term follow up. Hum Pathol 1989; 20: 758-764.
42. André S, Cunha F, Bernardo M et al. Mucinous carcinoma of the breast: a pathologic study of 82 cases. J Surg Oncol 1995; 58: 162-167.
43. du Toit RS, Locker AP, Ellis IO et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 1991; 17: 251-257.
44. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005; 23: 41-48.
45. Toikkanen S, Pylkkanen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 1997; 76: 1234-1240.
46. Pestalozzi BC, Zahrieh D, Mallon E et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. J Clin Oncol 2008; 26: 3006-3014.
47. Santiago RJ, Harris EE, Qin L et al. Similar long-term results of breastconservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: the University of Pennsylvania experience. Cancer 2005; 103: 2447-2454.
48. Tubiana-Hulin M, Stevens D, Lasry S et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 2006; 17: 1228-1233.
49. Mhuircheartaigh JN, Curran C, Hennessy E, Kerin MJ. Prospective matched-pair comparison of outcome after treatment for lobular and ductal breast carcinoma. Br J Surg 2008; 95: 827-833.
50. Rakha EA, El-Sayed ME, Powe DG et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 2008; 44: 73-83.
51. Bullet MA, Savignoni A, Pierga JY et al. High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies. Br J Cancer 2008; 98: 734-741.
52. Sastre-Garau X, Jouve M, Asselain B et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996; 77: 113-120.
53. Rakha EA, Gill MS, El-Sayed ME. The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. Breast Cancer Res Treat 2009; 114: 243-250.